Neuraminidase Inhibitors Drug Market Growth, Trends and Forecast by 2031

MARKET INTRODUCTION

Neuraminidase inhibitors (NAIs) are a class of drugs that prevent the neuraminidase enzyme. These are used as antiviral drugs as they block the influenza virus's purpose of viral neuraminidases by preventing its generation by budding from the host cell. One of the main advantages of neuraminidase inhibitors is a rare extension of resistance. The resistance against neuraminidase inhibitors occurs very rarely.

MARKET DYNAMICS

The growing prevalence of influenza and increasing awareness among the people are expected to increase the growth of the neuraminidase inhibitors drugs market. Additionally, other factors, such as an expanding number of hospital and diagnostic laboratories, development of healthcare infrastructure, especially in developing regions, and increasing population, are expected to provide growth opportunities. Moreover, favorable reimbursement policies and increasing R&D expenditure are expected to improve the neuraminidase inhibitors drugs market's overall growth.

MARKET SCOPE

The "Neuraminidase Inhibitors Drug Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Neuraminidase inhibitors drug market with detailed market segmentation by drug type, route of administration, and distribution channel. The neuraminidase inhibitors drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Neuraminidase inhibitors drug market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The neuraminidase inhibitors drug market is segmented on the drug type, route of administration, and distribution channel. Based on drug type, the market is segmented as oseltamivir, zanamivir, peramivir, and laninamivir. Based on route of administration, the market is segmented as parenteral, nasal, and oral. By distribution channel, it is further segmented as hospital pharmacy, retail pharmacy, online pharmacy, and other.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the neuraminidase inhibitors drug market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The neuraminidase inhibitors drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting neuraminidase inhibitors drug market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Neuraminidase inhibitors drug market in these regions.

MARKET PLAYERS

The report covers key developments in the Neuraminidase inhibitors drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from neuraminidase inhibitors drug market are anticipated to have lucrative growth opportunities in the future with the rising demand for diabetes drug type, route of administration, and distribution channel in the global market. Below mentioned is the list of few companies engaged in the neuraminidase inhibitors drug market.

The report also includes the profiles of key players in neuraminidase inhibitors drug market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•  GLAXOSMITHKLINE PLC
  
•  GILEAD SCIENCES
  
•  DAIICHI SANKYO
  
•  BIOCRYST LTD
  
•  F. HOFFMANN LA ROCHE
  
•  FOREST PHARMACEUTICALS INC.
  
•  ENDO PHARMACEUTICALS INC.
  
•  BRITANNICA
  
•  SHIONOGI CO
  
•  BIOTA HOLDINGS
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Neuraminidase Inhibitors Drug Report Scope